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Advances in understanding the molecular 
basis of frontotemporal dementia
Rosa Rademakers, Manuela Neumann and Ian R. Mackenzie
Abstract | Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. Until 
recently, the underlying cause was known in only a minority of cases that were associated with abnormalities 
of the tau protein or gene. In 2006, however, mutations in the progranulin gene were discovered as another 
important cause of familial FTD. That same year, TAR DNA-binding protein 43 (TDP-43) was identified as the 
pathological protein in the most common subtypes of FTD and amyotrophic lateral sclerosis (ALS). Since then, 
substantial efforts have been made to understand the functions and regulation of progranulin and TDP-43, as 
well as their roles in neurodegeneration. More recently, other DNA/RNA binding proteins (FET family proteins) 
have been identified as the pathological proteins in most of the remaining cases of FTD. In 2011, abnormal 
expansion of a hexanucleotide repeat in the gene C9orf72 was found to be the most common genetic cause 
of both FTD and ALS. All common FTD-causing genes have seemingly now been discovered and the main 
pathological proteins identified. In this Review, we highlight recent advances in understanding the molecular 
aspects of FTD, which will provide the basis for improved patient care through the development of more-targeted 
diagnostic tests and therapies.
Rademakers, R. et al. Nat. Rev. Neurol. 8, 423–434 (2012); published online 26 June 2012; doi:10.1038/nrneurol.2012.117
Introduction
Frontotemporal dementia (FTD) accounts for 5–15% of 
all cases of dementia, and is the second most common 
cause of dementia in the presenile age group (<65 years 
of age).1,2 FTD is a clinical syndrome that is characterized 
by progressive deterioration in behaviour, personality 
and/or language, with relative preservation of memory.3–5 
Clinical subtypes of FTD include the behavioural variant 
(bvFTD) and two forms of primary progressive aphasia: 
progressive nonfluent aphasia (PNFA) and semantic 
dementia. Additionally, FTD is often associated with an 
extra pyramidal movement disorder (parkinsonism or 
cortico basal syndrome) and/or motor neuron disease.6,7 
Given this variability in phenotype, it is not surprising that 
the molecular basis of FTD is also heterogeneous (Table 1).
A family history of FTD, often showing an autosomal 
dominant pattern of inheritance, is present in 25–50% of 
cases, indicating a strong genetic component.8,9 In 1998, 
mutations in the microtubule-associated protein tau 
(MAPT) gene on chromosome 17 were identified in a 
number of families with FTD and parkinsonism.10–12 Since 
then, 44 different MAPT mutations have been reported, 
accounting for 5–20% of cases of familial FTD.13,14 However, 
a number of chromosome 17-linked FTD f amilies 
remained in whom no MAPT mutations were found. 
A major breakthrough occurred in 2006 when the 
progranulin (GRN) gene was identified as the second 
FTD-related gene on chromosome 17.15,16 Indeed, GRN 
mutations account for an even larger proportion of FTD 
families than do mutations in MAPT.13 Much less common 
are mutations in the valosin-containing protein (VCP) 
gene, which cause the rare familial syndrome of inclusion 
body myopathy with Paget disease of bone and FTD,17 and 
a mutation in the gene encoding charged multi vesicular 
body protein 2B (CHMP2B), which was found in a large 
Danish FTD pedigree.18 In addition, several families with 
a combination of FTD and amyotrophic lateral sclero-
sis (ALS) have been reported to have genetic linkage to 
a locus on chromosome 9p.19–27 Despite years of intense 
effort by many research groups worldwide, the identity of 
the FTD–ALS gene on chromosome 9p remained elusive 
until 2011, when two independent studies identified the 
defect as being an expanded hexanucleotide repeat in a 
non coding region of the chromo some 9 open reading 
frame 72 (C9orf72) gene.28,29 Discovery of the C9orf72 
mutation has generated tremendous excitement in the 
FTD and ALS research communities, as it seems to be 
the most common genetic cause of both conditions.
The neuropathology associated with clinical FTD is 
also heterogeneous.30 A common feature of this disease 
is the relatively selective degeneration of the frontal 
and temporal lobes, and the term ‘frontotemporal lobar 
degeneration’ (FTLD) is often used for pathological con-
ditions that predominantly or commonly present with 
FTD. In addition, most cases of FTLD are found to have 
abnormal intra cellular accumulation of a disease-specific 
protein; as a result, classification of FTLD into broad cat-
egories on the basis of the molecular defect thought to be 
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most characteristic of the disease has become a popular 
approach.31,32 Initially, only the FTLD subgroup charac-
terized by the aggregation of hyperphosphorylated tau 
protein in neurons and glia, classified as FTLD-tau, was 
well-understood (Table 1). However, most cases of FTD 
are not associated with tau pathology, but are instead 
charac terized by neuronal inclusions that were originally 
identified using immuno histochemistry for ubiquitin 
—these cases were consequent ly termed FTLD-U.33,34 
Just months after publication of the studies in which 
the GRN mutations were discovered, another landmark 
paper reported TAR DNA-binding protein 43 (TDP-43) 
as the ubiquitinated pathological protein in most cases 
of FTLD-U (subsequently renamed FTLD-TDP), as well 
as in the majority of ALS cases.35,36 This finding provided 
Key points
 ■ All common frontotemporal dementia (FTD)-causing genes and signature 
proteins have now been discovered
 ■ Regulation of progranulin—one of the proteins affected in FTD—is one potential 
therapeutic strategy for this disorder
 ■ Expansion of a GGGGCC hexanucleotide repeat in a noncoding region of the 
C9orf72 gene is the most common genetic cause of FTD and amyotrophic 
lateral sclerosis (ALS)
 ■ The pathomechanism of C9orf72 mutation may include haploinsufficiency  
and/or toxic RNA foci
 ■ Most tau/TDP-negative frontotemporal lobar degeneration (FTLD) cases are 
characterized by inclusions that are immunoreactive for fused in sarcoma (FUS) 
and the other FET proteins (EWS and TAF15)
 ■ Differential involvement of the FET proteins in ALS with FUS mutations 
compared with FTLD-FUS implies that different pathomechanisms are involved 
in each disease
strong evidence that FTD and ALS are closely related con-
ditions with overlapping molecular pathogenesis. This 
concept was further strengthened in 2009 when, follow-
ing the discovery that mutations of the fused in sarcoma 
(FUS) gene cause autosomal dominant ALS,37,38 it was 
shown that the majority of the ~10% of FTLD patients 
who do not have either tau or TDP-43 pathology can be 
characterized by inclusions that are immuno reactive for 
FUS (a condition termed FTLD-FUS).39–41 More recently, 
the FUS-positive inclusions in FTLD-FUS were found to 
also stain positively for other members of the FET family 
of DNA/RNA-binding proteins, including Ewing sarcoma 
protein (EWS) and TATA-binding protein-associated 
factor 15 (TAF15).42
Over the past few years, the pace at which our knowl-
edge of the molecular genetics and neuropathology of 
FTD has advanced has been truly remarkable (Box 1). 
In just over 5 years, we have gone from knowing virtu-
ally nothing of the molecular basis of most cases of FTD, 
to now being able to determine the genetic cause in the 
majority of autosomal dominant families, and being able 
to assign virtually all cases of FTLD to one of three major 
pathological subtypes: FTLD-tau, FTLD-TDP or FTLD-
FUS.32 This insight is a crucial step towards improved care 
for patients with FTD, as it provides the basis for more-
informed counselling and the potential for more-specific 
diagnostic tests and targeted therapies. In this Review, we 
highlight several recent advances in our understanding 
of the molecular aspects of FTD, focusing on the dis-
covery of the C9orf72 mutation and the roles of pro-
granulin, TDP-43, and FUS and the other FET proteins 
in disease pathogenesis.
Table 1 | Genetic and clinical correlates of the molecular subtypes of FTD
Molecular 
classification
Pathological 
subtype*
Associated 
genes‡
Associated clinical phenotypes
bvFTD PNFA SD Parkinsonism MND
FTLD-tau
PiD
CBD
PSP
AGD
NFT-dementia
MSTD
WMT-GGI
MAPT +
+
+
+
+
+
+
+
(+)
+
+
+
(+)
(+)
+
+
+
+
+
ALS, PLS
PLS
PLS
PLS
PLS
FTLD-TDP
Type A
Type B
Type C
Type D 
(TARDBP)
GRN
C9orf72
VCP
(+)
+
+
+
+
+
+
(+)
+
+
+
+
(+)
ALS
ALS
ALS
FTLD-FUS
aFTLD-U
NIFID
BIBD
(FUS) (+)
+
+
+
+
+
ALS
PLS
ALS
FTLD-UPS
FTD-3 CHMP2B + (+) (ALS)
Brackets indicate rare associated genes or unusual phenotypes. *Characteristic pattern of pathology, not the clinical syndrome. ‡Genes in which variation may 
cause or increase the risk of FTD with the corresponding FTLD pathological subtype. FTLD with no inclusions is not included in this table as no genetic or clinical 
correlations have been made for this subtype. Abbreviations: aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitinated inclusions; AGD, argyrophilic 
grain disease; ALS, amyotrophic lateral sclerosis; BIBD, basophilic inclusion body disease; bvFTD, behavioural variant FTD; C9orf72, chromosome 9 open reading 
frame 72; CBD, corticobasal degeneration; CHMP2B, charged multivescicular body protein 2B; FTD, frontotemporal dementia; FTD-3, FTD linked to chromosome 3; 
FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; GRN, progranulin; MAPT, microtubule-associated protein tau; MND, motor neuron disease; MSTD, 
multiple system tauopathy with dementia; NFT, neurofibrillary tangle-predominant; NIFID, neuronal intermediate filament inclusion disease; PiD, Pick disease; PLS, 
primary lateral sclerosis; PNFA, progressive nonfluent aphasia; PSP, progressive supranuclear palsy; SD, semantic dementia; TARDBP and TDP, TAR DNA-binding 
protein; UPS, ubiquitin proteasome system; VCP, valosin-containing protein; WMT-GGI, white matter tauopathy with globular glial inclusions. 
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Advances in molecular genetics
GRN variants and progranulin regulators
In less than 6 years, 69 different pathogenic GRN muta-
tions have been reported in more than 230 families 
worldwide, accounting for 5–20% of cases of familial 
FTD and 1–5% of sporadic cases.13,43 Progranulin is a 
multi functional secreted growth factor that is expressed 
by many cell types including neurons.44 Pathogenic muta-
tions in GRN are of various types and occur throughout 
the gene, but all cause disease via haplo insufficiency.15,16 As 
a result, substantially reduced levels of pro granulin protein 
are consistently observed in plasma, serum and cerebro-
spinal fluid samples from symptomatic and asymptomatic 
GRN mutation carriers.45–47 On the basis of these findings, 
ELISAs to measure levels of pro granulin are being devel-
oped as an inexpensive alternative to classic sequencing 
analyses for diagnostic testing of patients with FTD.
Genetic modifiers and regulators of GRN expression
The clinical phenotype associated with GRN mutations is 
variable48–53 and penetrance is incomplete.54 Understand-
ing the factors that modify the expression of GRN 
mutations or regulate the normal GRN gene is of potential 
therapeutic importance. One such genetic factor is varia-
tion in the uncharacterized trans membrane protein 106B 
(TMEM106B) gene, which was recently uncovered in a 
genome-wide association study (GWAS) of patients with 
known FTLD-TDP pathology.55 Genetic variants in and 
near TMEM106B seem to protect from—or delay the 
onset of—FTD in indivi duals with pathogenic GRN muta-
tions, possibly by increasing the levels of pro granulin.55–58 
A number of microRNAs, including miR-29b and 
miR-107, have also been implicated in GRN regula-
tion.59,60 In addition, the minor T allele of genetic variant 
rs5848 (located in the 3' untranslated region of GRN) was 
found to increase the binding of miR-659 to GRN, thereby 
reducing the levels of progranulin.61 Genetic association 
studies have shown that carriers who are homozygous 
for the T allele of rs5848 have a threefold increased risk 
of develop ing FTLD-TDP compared with homozygous 
C-allele carriers,61 supporting a role for progranulin in 
sporadic FTD and possibly other neuro degenerative 
disease s such as Alzheimer disease.62–64 
GRN expression may also be modified by exogenous 
factors. GRN transcription was shown to be enhanced 
by small molecules such as suberoylanilide hydroxamic 
acid,65 whereas inhibitors of the vacuolar ATPase, and 
some alkalizing drugs, increased progranulin production 
and secretion through a translational mechanism.66
Cellular biology of progranulin
Substantial progress has been made in recent years 
towards our understanding of progranulin biology and 
the neuroprotective function of this protein. Addition 
of progranulin to stressed or progranulin-depleted neu-
ronal cells promotes neurite outgrowth.67–70 The neuro-
protective effects of progranulin might be attributable, at 
least in part, to the activation of cell signalling pathways 
involved in cell survival,67,71–74 and a role for progranulin 
in excitotoxicity and synaptic transmission has also been 
suggested.69,75 Importantly, sortilin (SORT1), a recep-
tor for neurotrophic factors in the brain, was identified 
in two independent studies as the first known receptor 
for progranulin.76,77 SORT1 has been shown to mediate 
pro granulin endocytosis and regulate the levels of pro-
granulin in vivo in mouse brain and in human plasma. 
Another study, published in 2011, reported that tumour 
necrosis factor receptors directly interact with pro-
granulin.78 The identification of progranulin receptors 
is exciting, as it opens new avenues in progranulin cell 
biology research and provides another potential route to 
FTD therapy.
C9orf72 mutation
Since 2006, increasing evidence has suggested the pres-
ence of a major locus for the combined phenotype of 
FTD and ALS on chromosome 9p21, but the disease 
mutation remained elusive (Box 2).19–27 The key to the 
identification of the disease-causing mutation was the 
observation of non-Mendelian inheritance of a GGGGCC 
hexanucleotide repeat located in a noncoding region of 
C9orf72 (Figure 1a) in a large FTD–ALS family desig-
nated VSM-20 (Vancouver, San Francisco and Mayo 
family 20).28 Using primers that flanked the repeat region, 
researchers discovered that all affected indivi duals in this 
family appeared homozygous by fluorescent PCR, yet 
affected children did not seem to inherit an allele from 
their affected parent. This finding suggested the presence 
Box 1 | Timeline of discoveries in the molecular pathogenesis of FTD
 ■ 1892: Arnold Pick describes lobar atrophy in a patient with presenile dementia 
and aphasia147
 ■ 1911: Alois Alzheimer characterizes Pick bodies using silver stains148
 ■ 1960s: Descriptions of PSP and CBD clinicopathological syndromes149,150
 ■ 1974: Different pathological subtypes of PiD described151
 ■ Mid-1980s–early 1990s: Identification of tau as major component of 
pathological lesions in Alzheimer disease, PiD, PSP and CBD152
 ■ 1990: Description of FTD cases without specific histopathology, termed DLDH153
 ■ Mid-1990s: Identification of FTLD-U, a subset of FTD with ubiquitin-
immunoreactive inclusions154
 ■ 1998: Mutations in the microtubule-associated protein tau gene (MAPT) 
identified in some families with FTD and parkinsonism genetically linked to 
chromosome 1710–12
 ■ 2004–2006: Recognition that most cases of DLDH are really FTLD-U, and that 
FTLD-U is the most common FTD-associated pathology34
 ■ 2006: Description of different patterns of FTLD-U that correlate with clinical 
phenotypes, genetic abnormalities and biochemical properties of inclusions116,118
 ■ 2006: Discovery that mutations in the progranulin gene (GRN) cause autosomal 
dominant FTD and explain all remaining chromosome 17-linked families15,16
 ■ 2006: TDP-43 identified as pathological protein in most cases of FTLD-U  
and ALS35,36
 ■ 2008: Identification of a subset of FTLD-U cases that lack TDP-43-
immunoreactive pathology, termed atypical FTLD-U, or aFTLD-U155,156
 ■ 2009: Discovery that most cases of tau-negative and TDP-43-negative FTLD 
have FUS-immunoreactive pathology (FTLD-FUS)39–41
 ■ 2011: Discovery that FTLD-FUS shows accumulation of other FET protein family 
members TAF15 and EWS42
 ■ 2011: FTD and ALS associated with a gene defect on chromosome 9p 
identified as a repeat expansion in C9orf7228,29
Abbreviations: ALS, amyotrophic lateral sclerosis; CBD, corticobasal degeneration; DLDH, 
dementia lacking distinct histopathology; FTD, frontotemporal dementia; FUS, fused in 
sarcoma; PiD, Pick disease; PSP, progressive supranuclear palsy; TDP-43, TAR DNA-binding 
protein 43.
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of a repeat expansion that was too large to be amplified by 
the PCR method, a suspicion that was confirmed using 
a repeat-primed PCR assay (Figure 1b) and Southern 
blot analysis. The polymorphic nature of this GC-rich 
hexanucleotide repeat was independently recognized by 
means of next-generation sequencing in a Welsh family 
with FTD–ALS,29 further implying a role for this genomic 
region in disease pathogenesis.
Mutation frequency
In the 6 months since discovery of the C9orf72 mutation, 
numerous FTD and ALS patients have been screened 
using the repeat-primed PCR assay for the presence of 
GGGGCC repeat expansions in C9orf72 (Table 2).28,29,79–95 
Mutation frequency has varied substantially among popu-
lations, with the highest frequency observed in genetically 
isolated populations from Finland and Sardinia, and in 
cohorts where all patients had a pathological diagnosis of 
FTLD-TDP (with or without ALS).28,29,82,86,89 The average 
mutation frequencies reported in North American and 
European populations are 37% for familial ALS, 6% for 
sporadic ALS, 21% for familial FTD, and 6% for spo-
radic FTD patients. In all series, the C9orf72 mutation 
is the most common genetic cause of familial ALS (more 
frequent than superoxide dismutase 1 mutations) and 
is comparable in frequency to GRN mutations in FTD 
families. To date, most of the patients included in the 
mutation screenings have been white; however, C9orf72 
repeat expansions have also been identified in patients of 
African American, Middle Eastern and Asian race.87,89,95 
Interestingly, independent of clinical presentation or 
ethnic origin, all C9orf72 mutation carriers inherit the 
expansion on the same genetic background, suggesting 
the presence of a common ancestor or, alternatively, the 
occurrence of multiple independent expansions on a 
fragile predisposing disease haplotype.89,96,97
Clinical phenotypes
Several groups from North America and Europe have 
published descriptions of the demographic, clinical and 
neuropathological features of their cohorts with the 
C9orf72 mutation.28,29,79–95 The clinical presentation of 
patients with this mutation is heterogeneous and highly 
variable between and within families. Patients may 
present with FTD, ALS or features of both. The FTD 
subtype is most often bvFTD, with PNFA being observed 
less frequently. ALS typically shows early involvement of 
both upper and lower motor neurons, and bulbar pres-
entation is particularly common.80,82,83,95 Several studies 
have found that ALS patients with the C9orf72 mutation 
have a slightly earlier onset and shorter disease duration 
than those without the mutation.80,82,83,85,92,95 In addition 
to FTD and ALS, other features in patients with the muta-
tion can include memory disorder,79,86,88,91,93,94 psycho-
sis,79,84,86,93,94 extrapyramidal movement disorder (usually 
an akinetic–rigid syndrome)79,83,84,86,91,93 and cere bellar 
signs.86 Symptoms tend to accumulate and phenotypes 
converge with disease progression, with most patients 
eventually developing some abnormalities of behaviour, 
language and motor function.79,81,83,86,95 Wide variation 
exists in the age at onset (27–83 years, mean ~50 years) 
and disease duration (1–22 years), and several studies 
have noted earlier disease onset in subsequent genera-
tions, consistent with the phenomenon of genetic antici-
pation.79,82,83,85,86,95 Assessment of patients with the C9orf72 
mutation by means of structural neuroimaging tends to 
show symmetrical bilateral atrophy, primarily affecting 
frontotemporal regions, but also involving other cerebral 
lobes and the cerebellum.79,86,88,93,98
Neuropathology
The neuropathology associated with the C9orf72 
mutation is a combination of FTLD-TDP and classic 
ALS.28,79,80,83,85,86,88,91,93–95,99,100 Regardless of the clinical 
pheno type, postmortem examination usually shows 
TDP-43-positive inclusions in a wide range of neuro-
anatomical regions, including the extramotor cerebral 
cortex, hippocampus, basal ganglia, substantia nigra, and 
lower motor neurons of the brainstem and spinal cord. 
In addition, a unique and highly characteristic feature 
of patients with the mutation is the presence of neuronal 
inclusions in the cerebellar granule cell layer, hippo campal 
pyramidal neurons and other neuroanatomical sites that 
stain positively for proteins of the ubiquitin proteasome 
system (such as ubiquitin, ubiquilins and p62) but are 
negative for TDP-43 (Figure 1c).28,79,80,83,85,86,88,91,93–95,99,100 
This consistent finding suggests that the mutation causes 
abnormal metabolism and accumulation of one or more 
as yet unidentified molecules, which could include mutant 
RNA or RNA-binding proteins, or protein products of 
aberrant splicing. To date, immunohistochemical studies 
using commercial antibodies against C9orf72 have failed 
to demonstrate any abnormal distribution or ac cumulation 
of this protein.28,80,83,86,88,94,95
Repeat size
All C9orf72 mutation screenings performed thus far 
have used the repeat-primed PCR method to detect the 
presence of a pathogenic GGGGCC repeat expansion. 
However, it is important to note that this method is only 
semiquantitative and that the characteristic stutter pattern 
Box 2 | History of the chromosome 9p FTD–ALS locus
Since 2006, at least 10 families with autosomal dominantly inherited FTD, 
ALS or both have been reported with conclusive or suggestive linkage to 
chromosome 9p.19–27 The minimal candidate region shared by all families was a 
3.7 Mb region containing only 10 known or predicted genes. In 2010, three GWAS in 
sporadic ALS populations identified a novel susceptibility locus on chromosome 9p 
that completely overlapped with the candidate region for familial FTD–ALS.157–159 
The strongest association was found in an ~80 kb haplotype block containing 
only three genes: MOBKL2B, IFNK and C9orf72. An independent GWAS in patients 
with pathologically confirmed FTLD-TDP nominated the same chromosomal 
region, implicating the chromosome 9p gene defect in sporadic forms of both 
FTD and ALS.55 However, despite concerted efforts by the FTD and ALS research 
communities, in-depth candidate-gene sequencing and targeted next-generation 
sequencing of the minimal candidate region failed to identify the causative 
mutation, suggesting that a complex mutational mechanism may be involved. In 
2011, an expanded hexanucleotide repeat in the noncoding region of C9orf72 was 
found to be the long-sought-after cause of FTD and ALS on chromosome 9p.28,29
Abbreviations: ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; GWAS, 
genome-wide association studies.
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on PCR (Figure 1b) cannot be used to determine the exact 
number of repeats. In one family, Southern blot analyses 
performed using DNA extracted from lymphoblast cell 
lines showed pathogenic repeat expansions of 700–1,600 
repeat units;28 however, the minimal repeat size required 
for disease manifestation may be consider ably smaller. 
As in other noncoding repeat expansion disorders, evi-
dence for somatic instability of the C9orf72 repeat exists.28 
Consequently, repeat lengths may vary among different 
tissues within the same individual, making it difficult 
to accurately size the repeat and determine correlations 
between genetics, clinical presentation and pathology.101–103 
Combined with the aforementioned technical chal-
lenges, our lack of knowledge of the minimal pathogenic 
repeat size raises important questions regarding genetic 
testing for this common mutation, particularly in the 
context of predictive genetic testing. Accurate sizing of 
the expanded repeat in large FTD and ALS patient series 
will be crucial to establish a reliable cut-off size, which will 
assist when counselling individuals who are under going 
genetic testing. Future studies should also determine 
whether the repeat length contributes to the variability 
in onset age and clinical presentation, or whether other 
genetic and/or environmental modifiers are involved.
Disease mechanism
C9orf72 is a completely uncharacterized protein, the 
function of which is unknown. Two different isoforms 
of the protein are predicted to be generated from a total of 
three different C9orf72 transcripts;28 however, the relative 
expression of each of these transcripts in individual brain 
regions has not been studied. Several groups have shown 
~50% loss of at least one C9orf72 transcript in expanded-
repeat carriers, presumably owing to interference of the 
expanded GC-rich repeat with C9orf72 transcription 
regulation.28,29,85 Although these findings support a pos-
sible loss-of-function disease mechanism, the accumu-
lation of transcripts containing the GGGGCC repeat as 
nuclear RNA foci in the frontal cortex and spinal cord of 
C9orf72 mutation carriers has also been demon strated 
(Figure 1d), suggesting a possible toxic RNA gain-of-
function disease mechanism.28 On the basis of current 
knowledge of the pathogenesis of other noncoding repeat 
expansion disorders, one might suggest that these RNA 
foci will alter the function of one or more RNA-binding 
proteins, resulting in downstream changes in gene expres-
sion and/or alternative splicing of a range of transcripts.104 
A number of cellular and animal models, involving either 
elimination of C9orf72 expression or overexpression of 
a bC9orf72 genomic locus
1a 1b 2 3 4 5 6 7 8 9 10 11
ATG TAA
(GGGGCC)n
c d
Expanded C9ofr72 repeat
Normal C9orf72 repeat
0 500400300200100 600
Figure 1 | Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes FTD and ALS linked to 
chromosome 9p. a | Genomic structure of C9orf72, showing coding (yellow) and noncoding (blue) exons, the position of the 
start codon (ATG) and stop codon (TAA), and the (GGGGCC)n repeat in the intronic region between exons 1a and 1b (star).  
b | PCR products of repeat-primed PCR reactions zoomed to 2,000 relative fluorescence units show stutter amplification in 
an FTD patient with the pathogenic expanded C9orf72 repeat (top) and an FTD patient with a normal C9orf72 repeat length 
(bottom). c | In addition to FTLD-TDP and ALS pathology, all patients with the C9orf72 mutation show a unique pattern of 
ubiquitin-positive (brown), TDP-43-negative neuronal inclusions in the cerebellar granule layer and other specific 
neuroanatomical regions. d | RNA foci, visualized using a Cy3-labelled (GGCCCC)4 oligonucleotide probe (red), in the nuclei 
of two lower motor neurons from a patient with FTD–ALS carrying the expanded GGGGCC repeat in C9orf72. Abbreviations: 
ALS, amyotrophic lateral sclerosis; C9orf72, chromosome 9 open reading frame 72; FTD, frontotemporal dementia;  
TDP, TAR DNA-binding protein.
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human C9orf72 containing expanded GGGGCC repeats, 
are currently being generated to determine the contribu-
tion of each disease mecha nism to neurodegeneration 
and TDP-43 aggregation.
Other genes and genetic risk factors
FTD-related genes
With the identification of the repeat expansion in C9orf72, 
we have now accounted for all previously published FTD 
families with genome-wide linkage. Although it is unlikely 
that any other common FTD-related genes exist, rare 
mutations in other genes could explain a small number 
of the remaining families. Combinations of genetic vari-
ants and environmental factors are likely to be responsible 
for disease in the majority of patients with sporadic FTD. 
The use of whole-exome sequencing and whole-genome 
sequencing will greatly facilitate the discovery of rare 
genetic defects in the future, as was recently demonstrated 
with the identification of mutations in the colony stimulat-
ing factor 1 receptor gene as the cause of hereditary diffuse 
leukoencephalopathy with spheroids,105 a disorder with 
variable clinical presentation that includes features of FTD. 
Additional GWAS—such as a large collaborative study that 
is currently underway, which includes more than 2,500 
samples from patients with FTD—may identify additional 
genetic risk factors.
ALS-related genes
Other rare genetic causes of FTD that have been identi-
fied in recent years include TARDBP and FUS, although 
Table 2 | Frequency of the C9orf72 repeat expansion in FTD and ALS patient populations
Study region* Familial FTD Sporadic FTD Familial ALS Sporadic ALS Cases 
excluded‡
n C9orf72 
mutation
n C9orf72 
mutation
n C9orf72 
mutation
n C9orf72 
mutation
Europe
Finland29,89 27 13 (48.1%) 48 9 (18.8%) 112 52 (46.4%) 289 61 (21.1%) Yes
Ireland81 NA NA NA NA 47 18 (38.3%) 386 19 (4.9%) NS
UK83,§ NA NA NA NA 63 27 (42.9%) 500 35 (7.0%) No
UK88,§ 93 12 (12.9%) 163 6 (3.7%) NA NA NA NA No
UK94,§ 161 20 (12.4%) 209 16 (7.7%) NA NA NA NA No
Netherlands89,93 129 37 (28.7%) 224 5(2.2%) NA NA NA NA Yes
Belgium85,|| 75 12 (16.0%) 230 9 (3.9%) 15 7 (46.7%) 122 6 (4.9%) Yes
France89 50 22 (44.0%) 150 14 (9.3%) NA NA NA NA Yes
Germany29,82,89 29 4 (13.8%) NA NA 69 15 (21.7%) 421 22 (5.2%) Yes
Italy 
(mainland)29,82,89,92
NA NA NA NA 120 45 (37.5%) 1,523 55 (3.6%) Yes
Italy 
(Sardinia)82,89,92
NA NA NA NA 21 12 (57.1%) 133 9 (6.8%) Yes
Italy (Sicily)92 NA NA NA NA NA NA 101 5 (4.9%) Yes
Greece90 NA NA NA NA 10 5 (50.0%) 136 11 (8.1%) NS
North America
USA28,79 171 20 (11.7%) 203 6 (3.0%) 34 8 (23.5%) 195 8 (4.1%) No
USA29,89,¶ NA NA NA NA 163 59 (36.2%) 1014 56 (5.5%) NS
Canada95 NA NA NA NA 62 17 (27.4%) 169 6 (3.6%) No
Canada28,86,# 26 16 (61.5%) 3 0 (0.0%) NA NA NA NA No
USA28,# 40 9 (22.5%) 53** 8 (15.1%) NA NA NA NA No
USA80,# 18 6 (33.3%) 6 0 (0.0%) 14 6 (42.9%) 43** 5 (11.6%) NS
Other regions
Israel89 NA NA NA NA 14 3 (21.4%) NA NA NS
India89 NA NA 31 0 (0.0%) NA NA 31 0 (0.0%) NS
Asia89,‡‡ 3 2 (66.7%) 10 0 (0.0%) 20 1 (5.0%) 238 0 (0.0%) NS
Guam89 NA NA NA NA NA NA 90 0 (0.0%) NS
Australia89 NA NA NA NA NA NA 263 14 (5.3%) NS
*Only geographical regions with at least 10 FTD or ALS patients are listed. ‡In studies in which patients known to carry mutations in other genes were excluded, the 
frequency of C9orf72 repeat expansions are overestimated. §Cohorts are part of a larger series of UK patients which are grouped in Majounie et al.89 with highly 
comparable mutation frequencies.  || Numbers do not include 23 patients with both FTD and ALS, of which 85.7% of familial and 6.3% of sporadic patients were 
C9orf72 mutation carriers. ¶ In the sporadic ALS cohort, 5.4% (48 of 890) of white patients and 4.1% (2 of 49) of African American patients carried a C9orf72 repeat 
expansion. #Only included patients with a pathological diagnosis of FTLD-TDP.  ** Includes individuals for whom no information on family history was available.  
‡‡The geographical origin of the Asian patients was not reported in detail; however, the familial ALS patient carrying the C9orf72 repeat expansion was Japanese. 
Abbreviations: ALS, amyotrophic lateral sclerosis; C9orf72, chromosome 9 open reading frame 72; FTD, frontotemporal dementia; NA, not applicable;  
NS, not stated.
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mutations in each of these genes usually cause a pure 
ALS phenotype.37,38,106,107 In 2011, UBQLN2, a gene that 
encodes a member of the ubiquilin family, which is 
involved in the degradation of ubiquitinated proteins, 
was also added to the list of ALS–FTD-related genes.108 
Progressive dementia with abnormalities in both behav-
iour and executive functions were reported in ~20% 
of UBQLN2 mutation carriers; however, none of these 
patients presented with FTD alone.
Advances in molecular pathology
TDP-43
TDP-43 is a highly conserved, predominantly nuclear 
protein that can shuttle between the nucleus and cyto-
plasm. This protein has a number of well-described func-
tions in RNA regulation, such as the control of splicing, 
and in mRNA transport and stability; however, the full 
complexity of TDP-43 function is only just emerging.109–111
FTLD-TDP
Abnormal accumulation of TDP-43 in neuronal and 
glial inclusions is the characteristic neuropathologi-
cal feature in ~50% of patients with FTD (a condition 
termed FTLD-TDP) and in the vast majority of ALS 
cases.31,35,36 Pathological modifications of TDP-43 in these 
disorders include a redistribution of the protein from the 
nucleus to the cytoplasm in cells with inclusions, as well 
as hyperphosphorylation, ubiquitination and N-terminal 
truncation of the protein.36 FTLD-TDP includes sporadic 
and genetic forms, with mutations having been identi-
fied in GRN, VCP and TARDBP, along with the recently 
recognized C9orf72 repeat expansion (as described 
above).28,29,112–115 On the basis of the morphology and 
anatomical distribution of TDP-43 pathology, four dis-
tinct FTLD-TDP subtypes can be recognized.116–118 The 
relevance of this heterogeneity is supported by clinical 
and genetic correlations (Table 1), as well as by emerging 
evidence for distinct biochemical properties of TDP-43 
in the different subtypes.36,118,119
Pathogenesis of TDP-43 proteinopathies
The neuropathological findings in patients with FTLD-
TDP implicate both loss-of-function and gain-of-
function mechanisms in TDP-43-associated cell death. 
Numerous research groups worldwide are focused on 
addressing these mechanisms, and detailed discussions 
of TDP-43 pathogenesis have been published else-
where.120–122 Briefly, current in vivo models provide evi-
dence for both scenarios: neither reduced nor increased 
expression of the tightly autoregulated TDP-43 protein 
is well-tolerated.120–122 However, no model has fully 
recapitu lated the neuropathological and biochemical 
features of human TDP-43 related diseases. Although 
the presence of TARDBP mutations is a clear indicator 
that dysfunction of TDP-43 is directly linked to neuro-
degeneration, the functional consequences of TARDBP 
mutations are still unresolved. No solid evidence that 
TARDBP mutations act through a toxic gain-of-function 
mechanism exists, and no functional consequences of 
TARDBP mutations on the processing of selected RNA 
targets have been reported. However, studies that used 
crosslinking immuno precipitation and high- throughput 
sequencing have identified more than 6,000 RNA targets 
of TDP-43.110,111 A major challenge is to dissect the 
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Figure 2 | Distinct pathomechanisms of ALS-FUS and FTLD-FUS. The FET protein family 
members FUS (blue), EWS (green) and TAF15 (red) all contain a proline–tyrosine NLS 
(represented as a triangle) that binds to the receptor protein Trp, which mediates the 
transport of these proteins into the nucleus. a | Under physiological conditions,  
the FET proteins bind normally to Trp (top panel), and all have predominantly nuclear 
localization (bottom panels). b | In ALS-FUS, the NLS of FUS is disrupted owing to 
mutations (rectangle), leading to impaired interaction with Trp and lack of nuclear 
import of FUS. Consequently, FUS accumulates as a cytoplasmic inclusion, with 
normal nuclear transport of TAF15 and EWS (bottom panels). c | Patients with FTLD-
FUS/FTLD-FET show co-accumulation of all FET proteins in cytoplasmic inclusions 
(bottom images), which may be explained by either of two broad scenarios: 
alterations of Trp itself, such as by genetic variations, reduced expression levels or 
post-translational modifications (scenario 1), or post-translational modifications of 
FET proteins with altered Trp binding (scenario 2). All photomicrographs show a 
single neuron with a cytoplasmic inclusion (arrow) and nucleus (asterisk), 
immunostained for the indicated FET protein (brown stain). Abbreviations: ALS, 
amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration; FUS, fused 
in sarcoma; NLS, nuclear localization signal; Trp, transportin-1.
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indivi dual pathways that are regulated by TDP-43, and 
to identify possible disease-relevant RNA targets.
Another important but unresolved issue is the role of 
TDP-43 in the non-TARDBP-associated genetic forms 
of FTLD-TDP. The fact that disease associated with muta-
tions in GRN, VCP or C9orf72 is consistently character-
ized by the presence of TDP-43 pathology suggests that 
dysregulation of TDP-43 might be a crucial common 
downstream mechanism leading to cell death in each of 
these disorders. However, the relevance of TDP-43 accu-
mulation in C9orf72 mutation carriers has recently been 
challenged by the identification of TDP-43-negative, 
 ubiquitin-positive pathology that is more abundant than 
the TDP-43 pathology in distinct brain regions (Figure 1c), 
raising the possibility that, in these cases, another uniden-
tified protein—or  proteins—might be more important 
than TDP-43 in the pathogenesis.28,79,80,83,85,86,88,91,93–95,99,100
FUS and other FET proteins
FUS belongs to the FET protein family, which also includes 
EWS, TAF15, and the Drosophila orthologue of FUS, 
Cabeza. These proteins are highly conserved, ubiquitously 
expressed, predominantly nuclear (Figure 2a), multi-
functional DNA/RNA-binding proteins123 that can bind 
to a large number of partially overlapping RNA targets.124
FTLD-FUS
Early in 2009, FUS mutations were reported to be the 
cause of ~3% of familial ALS cases in which the associ-
ated pathology was characterized by FUS-positive, TDP-
43-negative inclusions.37,38 These cases were consequently 
termed ALS-FUS. Subsequently, FUS was found to be the 
most characteristic marker for the pathology in many 
of the remaining tau/TDP-negative FTLD cases, which 
include three closely related but distinct clinicopatho-
logical entities: atypical FTLD-U (aFTLD-U), neuronal 
intermediate filament inclusion disease, and baso-
philic inclusion body disease.39–41,125 The identification 
of FTLD-FUS as a new molecular subgroup32 provided 
further evidence that FTD and ALS are closely related 
conditions, and emphasized the pathogenic role of RNA-
binding proteins in these disorders. However, despite 
some overlap in the phenotype and pathological features 
of FTLD-FUS and ALS-FUS, marked differences were also 
observed.126,127 Moreover, after additional cases were 
reported, it became evident that ALS with FUS pathol-
ogy is almost always caused by a FUS mutation, whereas 
cases of FTLD-FUS tend to be sporadic, with none yet 
associat ed with a genetic abnormality of FUS.39–41,125 
Further evidence for different pathomechanisms in 
the two disorders was provided via a study that inves-
tigated FET protein members (other than FUS) in a 
series of ALS-FUS and FTLD-FUS cases.42 In ALS-FUS 
with a range of different mutations, no co-accumulation 
of other FET proteins into FUS-positive inclusions was 
found, with only nuclear staining of TAF15 and EWS 
being observed (Figure 2b). In striking contrast, in all 
FTLD-FUS subtypes, TAF15 and EWS were found to 
co-accumulate in FUS-positive cytoplasmic inclusions, 
and inclusion- bearing cells showed reduced levels of 
nuclear staining of all three FET proteins, particularly 
TAF15 (Figure 2c).
The addition of TAF15 and EWS to the growing list of 
neurodegeneration-associated RNA-binding proteins is 
further supported by studies in which TAF15 was iden-
tified as a candidate through a yeast functional screen 
to identify RNA binding proteins with similar function to 
TDP-43 and FUS.128 Descriptions of genetic variants (of 
undetermined pathogenic relevance) in TAF15 and EWSR1 
in a small number of ALS cases provide further evidence 
for a role for these proteins in neurodegeneration.129,130 
Although the roles of FUS, TAF15 and EWS in FTLD-FUS 
remains to be elucidated, the term FTLD-FET now seems 
more appropriate for this molecular FTLD subgroup.
Pathogenesis of FUS proteinopathies
The differences in the molecular pathology of ALS-FUS 
and FTLD-FUS imply that different pathological processes 
underlie inclusion formation and cell death in each dis-
order: ALS-FUS might be restricted to dysfunction of FUS, 
whereas FTLD-FUS may involve dysfunction of all FET 
proteins (Figure 2).
In ALS-FUS, mutations in the C-terminus of the FUS 
protein disrupt a region characterized as a nonclassi-
cal nuclear localization sequence. This disruption leads 
to impaired transportin-mediated nuclear import of 
FUS, with redistribution of the protein to the cytoplasm 
(Figure 2b).131,132 Importantly, localization of other FET 
proteins is not altered under these conditions.42 The 
degree of impairment in FUS nuclear transport varies 
among different FUS mutations, but correlates with the 
observed variability in disease course associated with dif-
ferent mutations, and with distinct pathological patterns 
of ALS-FUS pathology.126 This finding provides strong evi-
dence that impaired nuclear import of FUS is a key event 
in ALS-FUS disease pathogenesis.
In FTLD-FUS, a more general defect of transportin-
mediated nuclear import that affects the distribution of 
all FET proteins is postulated, with two plausible scenarios 
(Figure 2c). First, a primary defect of transportin itself, 
resulting either from genetic variations in the transportin 
gene (TNPO1) or from post-translational modifications 
or altered expression levels of transportin protein, could 
lead to reduced efficiency of nuclear import of all FET 
proteins. In this scenario, however, one might also expect 
alterations in the subcellular distribution of other trans-
portin cargos such as hnRNPA1, which has not been sup-
ported by preliminary data.42 Second, the normal nuclear 
import of FET proteins might be affected by abnormal 
post- translational modifications of FET proteins, such as 
arginine methyla tion or phos phorylation, which have been 
shown to modulate nucleocytoplasmic transport, protein–
protein interaction and protein stability.123,133–139 So far, 
bio chemical analysis of protein extracted from FTLD-
FUS brains has revealed increased insolubility of all FET 
proteins, without other obvious disease-associated changes 
such as truncation or abnormal phosphorylation;40,42,140 
however, more-detailed biochemical analyses are required.
The downstream effects of redistribution of FUS or 
all FET proteins in the pathogenesis of ALS-FUS and 
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Review criteria
References for this Review were identified by searching 
PubMed using the terms “frontotemporal dementia”, 
“frontotemporal lobar degeneration”, “progranulin”, 
“TDP-43”, “FUS”, “FET”, “C9orf72”, “genetics”, “molecular” 
and “pathology”. Only articles published in English from 
2006 to April 2012 were reviewed. Additional papers were 
identified from the reference lists of identified articles.
FTLD-FUS, respectively, have not been determined. As 
in the case of TDP-43, either a gain of toxic properties or a 
loss of function owing to sequestration of these proteins in 
aggregates is plausible. Results from initial in vivo models 
of ALS-FUS have been inconsistent and the mechanisms 
remain unresolved.122,141
Molecular correlates of FTD phenotypes
Each of the molecular subtypes of FTLD pathology is 
associated with a range of clinical features and may be 
caused by defects in specific genes (Table 1). However, 
prediction of the underlying molecular pathology or 
genetics on the basis of pattern of inheritance and clini-
cal features is often imprecise.142,143 Semantic dementia is 
usually sporadic and associated with FTLD-TDP type C, 
with fewer cases having the pathology of classical Pick 
disease. Cases of sporadic PNFA are more likely to have 
FTLD-tau than FTLD-TDP, but bvFTD can be associ-
ated with any of the major pathologies. Early-onset 
bvFTD with severe psycho behavioural abnormality, but 
with minimal motor features or aphasia, is characteris-
tic of the aFTLD-U subtype of FTLD-FUS. When FTD 
is combined with ALS, the pathology is usually FTLD-
TDP, whereas FTD with prominent parkinsonism is more 
often FTLD-tau (namely, progressive supranuclear palsy 
or cortico basal degeneration). In families with autosomal 
dominant inheritance of bvFTD or PNFA without marked 
motor dysfunction, the underlying gene defect may be a 
mutation in C9orf72, GRN or MAPT. When parkinsonism 
or primary lateral sclerosis are also prominent features, 
a MAPT mutation is more likely, whereas coexistence of 
classical ALS in a family strongly suggests a C9orf72 muta-
tion. Further research is required to improve our under-
standing of the correlation between molecular basis and 
clinical phenotypes of the different FTD subgroups.
Conclusions and future directions
The past 6 years have seen remarkable progress in our 
understanding of the molecular basis of FTD. Apparently, 
all common FTD-causing genes have now been discovered 
and the major pathological proteins identified. Although 
many aspects of specific pathogenic mechanisms remain 
to be resolved, we are already in a position to begin trans-
lating this newly acquired knowledge into improved 
patient care. The recent discoveries of mutations in GRN 
and C9orf72 will enable more-informed genetic counsel-
ling, and our improved knowledge of the pathological 
proteins in FTD is driving attempts to develop disease-
specific, molecular-based diagnostic tests, such as the 
quantification of total or pathological protein species in 
biofluids.144,145 Recognition of progranulin insufficiency 
as an important patho mechanism in familial FTD and 
some sporadic forms of FTD, combined with improved 
understanding of progranulin regulation and cell biology, 
has already led to initial plans for progranulin-based clini-
cal trials.146 The identification of a role for TDP-43, FET 
proteins and C9orf72 in FTD has opened up new avenues 
of research related to RNA regulation. Finally, a greater 
appreciation of the overlap between FTD and ALS is now 
bringing research and patient care in these disorders 
closer together. Hopefully, patients with FTD will soon 
ex perience real benefits from these and future advances.
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